The first innovative anti allergy drug for children in China
It is the first and only standardized sublingual desensitizer approved for production and sales in China. The country has implemented a 4-year new drug monitoring period for this drug.
Relying on the world leading allergen drug technology platform with multiple intellectual property rights protection, it has the ability to independently research and develop innovative drugs that are rare and have been verified in Chinese pharmaceutical enterprises.
The company has a professional team with global R&D vision and rich operating experience.
Investment time: March 2011 .
Reason for investment:
The incidence rate of children with allergic rhinitis and asthma in China is 30-40%, and the overall market demand is growing continuously.
The age of clinical research covers 4 years old, so it can be used in pediatrics. The drug drop rate is low, and it can enjoy the market alone.
Listed on Shenzhen Growth Enterprise Market on January 21, 2014, sponsored by Zhongtian Guofu, stock code: 300357.SZ.
On May 26, 2015, the SciNova fund recovered 430 million yuan, 17 times the income.